Cognito Therapeutics today unveiled new findings from its ongoing research into the Spectris neuromodulation system at the Alzheimer’s Association International Conference (AAIC) 2025. The company shared five poster presentations reinforcing the clinical efficacy and neuroprotective potential of its non-invasive therapy for Alzheimer’s disease.
Spectris delivers proprietary gamma frequency (40 Hz) light and sound stimulation, designed to restore disrupted brain activity associated with central nervous system (CNS) disorders. The stimulation induces EEG-confirmed gamma oscillations, which have been shown to improve structural and functional brain integrity in Alzheimer’s patients.
Findings from the OVERTURE feasibility trial and its open-label extension (OLE) demonstrated that Spectris led to significant "time saved" in disease progression. Over six months, Spectris slowed both structural and functional decline, while the 18-month data showed sustained benefits in cognitive, functional, and imaging-based measures.
Clinical Highlights from OVERTURE OLE:
8.66 months saved in daily living activities
9.93 months saved in cognitive decline
7.48 months saved in whole-brain volume loss
Additionally, MRI analyses revealed that Spectris preserved white matter and myelin integrity across several brain regions, suggesting a broad structural neuroprotective effect linked to its gamma-frequency stimulation.
Patient-centered outcomes were also assessed using the "What Matters Most" (WMM) framework. Spectris demonstrated significantly reduced decline in 12 of 41 WMM domains, including:
Independence in daily activities
Communication
Emotional stability
Social engagement
Further data showed that combined light and sound stimulation produced more robust gamma brain oscillations across broader regions than light or sound alone. Importantly, participant adherence exceeded 85%, underscoring Spectris' feasibility for at-home, daily use.
“The results shared at AAIC further strengthen the case for Spectris as a promising non-invasive approach that not only slows cognitive decline but also preserves brain structure,” said Christian Howell, CEO of Cognito Therapeutics. “We believe neuromodulation has the potential to redefine Alzheimer’s care by combining safety, efficacy, and real-world usability.”“We are seeing consistent clinical, imaging, and patient-reported benefits with Spectris,” added Dr. Ralph Kern, Chief Medical Officer at Cognito Therapeutics. “These findings validate our approach and support our continued progress toward regulatory engagement.”